SS-31 (also known as Elamipretide) is a synthetic peptide originally developed by researchers studying mitochondrial dysfunction in degenerative diseases. It is a tetrapeptide composed of D-Arg-dimethylTyr-Lys-Phe-NH2, and it has a unique ability to target the inner mitochondrial membrane, where it binds to a key phospholipid called cardiolipin.
What makes SS-31 different from other peptides is its cell-penetrating and mitochondria-selective action. Once inside the mitochondria, it directly stabilizes cardiolipin, which is essential for maintaining mitochondrial structure, energy production, and resistance to oxidative damage.
The primary mechanism of SS-31 is its interaction with cardiolipin, a unique phospholipid found exclusively in the inner mitochondrial membrane. Cardiolipin is critical for:
Mitochondrial respiration and ATP production
Maintaining the shape and integrity of mitochondria
Anchoring respiratory complexes of the electron transport chain
As we age or experience oxidative stress, cardiolipin becomes damaged or oxidized, leading to:
Mitochondrial membrane leakage
Reduced ATP production
Increased ROS (reactive oxygen species)
Cell death or dysfunction
SS-31 works by:
Binding to cardiolipin to preserve mitochondrial structure
Preventing peroxidation of cardiolipin
Enhancing efficiency of the electron transport chain
Improving ATP synthesis
Reducing production of ROS
In short, SS-31 restores mitochondrial efficiency while protecting cells from oxidative stress and premature death.
Clinical and preclinical studies on SS-31 suggest a broad range of potential benefits, especially in conditions involving mitochondrial dysfunction and oxidative stress.
By improving mitochondrial ATP output, SS-31 can increase physical and mental energy, particularly in those with chronic fatigue, aging-related mitochondrial decline, or degenerative diseases.
Studies in older adults show that SS-31 can restore exercise tolerance and muscle function, improving oxygen utilization and mitochondrial respiration during physical activity.
In models of Alzheimer’s, Parkinson’s, and stroke, SS-31 reduced neuronal loss and improved cognitive function. It also shows promise in reducing brain fog and protecting against neuroinflammation.
SS-31 has been studied for its ability to:
Reduce ischemia-reperfusion injury
Improve cardiac output
Prevent mitochondrial-driven heart failure
It has been used in early human trials in patients with Barth syndrome, heart failure, and coronary artery disease.
By protecting mitochondrial integrity, SS-31 slows telomere shortening, cellular senescence, and DNA damage—hallmarks of aging. It also improves skin elasticity, reduces frailty, and enhances metabolic flexibility.
Mitochondrial dysfunction plays a key role in retinal degeneration. SS-31 has been studied in conditions like age-related macular degeneration (AMD) and dry eye, with positive results.
While more human data is needed, SS-31 has shown potential in:
Chronic fatigue syndrome / ME/CFS
Fibromyalgia
Post-viral syndromes
Mitochondrial myopathies
Parkinson’s and Alzheimer’s disease
Heart failure or cardiomyopathy
Type 2 diabetes and metabolic syndrome
Aging-related frailty
Long COVID (hypothesized mechanism)
It is also being explored by biohackers and longevity enthusiasts as a mitochondrial rejuvenation tool.
SS-31 is not a growth factor or hormone-mimicking peptide like CJC-1295 or BPC-157. Its value lies in its unique mitochondria-targeting mechanism, giving it a niche but critical role in peptide-based regenerative medicine.
| Peptide | Primary Benefit | Target |
|---|---|---|
| SS-31 | Mitochondrial health, ATP production | Inner mitochondrial membrane |
| BPC-157 | Tissue healing, anti-inflammation | Gut, tendons, ligaments |
| TB-500 | Cellular repair, actin regulation | Muscle, fascia |
| MOTS-c | Metabolic health, insulin sensitivity | Mitochondrial gene expression |
| Epitalon | Telomere support, anti-aging | Pineal gland, gene expression |
SS-31 has demonstrated a strong safety profile in both animals and human studies.
Injection site irritation
Temporary fatigue (likely due to cellular detoxification)
Mild dizziness
There have been no reports of systemic toxicity or mitochondrial overload. In human trials using IV and SubQ doses up to 40mg/day, SS-31 was well tolerated.
